Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Revelation Biosciences Inc (REVB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: REVB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20.73
1 Year Target Price $20.73
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22.22% | Avg. Invested days 8 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.45M USD | Price to earnings Ratio - | 1Y Target Price 20.73 |
Price to earnings Ratio - | 1Y Target Price 20.73 | ||
Volume (30-day avg) 1 | Beta -0.09 | 52 Weeks Range 0.71 - 34.24 | Updated Date 06/30/2025 |
52 Weeks Range 0.71 - 34.24 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -82.07 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -54.68% | Return on Equity (TTM) -233.26% |
Valuation
Trailing PE - | Forward PE 0.89 | Enterprise Value -197440 | Price to Sales(TTM) 2.88 |
Enterprise Value -197440 | Price to Sales(TTM) 2.88 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.02 | Shares Outstanding 4603800 | Shares Floating 941937 |
Shares Outstanding 4603800 | Shares Floating 941937 | ||
Percent Insiders 2.27 | Percent Institutions 3.17 |
Analyst Ratings
Rating 1 | Target Price 20.73 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Revelation Biosciences Inc
Company Overview
History and Background
Revelation Biosciences Inc. is a clinical-stage biopharmaceutical company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Founded to address unmet needs in respiratory infections, inflammation, and other immunological diseases.
Core Business Areas
- Respiratory Infections: Developing therapies to prevent or treat respiratory viral infections, including influenza and COVID-19.
- Inflammation: Exploring immunomodulatory approaches to treat inflammatory conditions.
- Immunological Diseases: Researching and developing therapies for other immunological diseases.
Leadership and Structure
James Rolke serves as the Chief Executive Officer. The company has a board of directors overseeing its strategic direction and key functional departments responsible for research, development, clinical trials, and operations.
Top Products and Market Share
Key Offerings
- REVTx-99a: A nasal spray currently in clinical development to prevent or treat respiratory viral infections, including influenza A (H3N2). Data about market share and direct revenue is currently unavailable because it is still in development, therefore there are no sales. Competitors include companies that produce or are developing influenza treatments like Roche (Tamiflu) and Gilead (Tamiflu).
- REVTx-300: Focuses on inflammatory bowel disease (IBD). Data about market share and direct revenue is currently unavailable because it is still in development, therefore there are no sales. Competitors include companies that produce or are developing IBD treatments, like Johnson & Johnson (Remicade) and AbbVie (Humira).
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing significant growth due to increasing prevalence of infectious and immunological diseases, advancements in immunology, and rising healthcare expenditure. The competitive landscape is intense, with numerous companies vying for market share in various therapeutic areas.
Positioning
Revelation Biosciences is positioned as a developer of novel immunologic therapies. Its competitive advantage lies in its unique immunomodulatory approach.
Total Addressable Market (TAM)
The TAM for infectious and immunological diseases is substantial, estimated to be billions of dollars annually. Revelation Biosciences is positioned to capture a portion of this market with successful development and commercialization of its pipeline products.
Upturn SWOT Analysis
Strengths
- Novel immunomodulatory approach
- Experienced management team
- Clinical-stage pipeline products
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- High reliance on clinical trial success
- Small market capitalization
- Dependence on partnerships or funding
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Government funding and grants
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established players
- Patent challenges
Competitors and Market Share
Key Competitors
- JNJ
- ABBV
- GILD
- RHHBY
Competitive Landscape
Revelation Biosciences faces intense competition from larger pharmaceutical companies with established products and significant resources. Its success depends on demonstrating superior efficacy and safety of its pipeline candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not yet established given its stage of development.
Future Projections: Future projections depend heavily on clinical trial outcomes and potential partnerships. Analyst estimates can be obtained from financial news. However, these estimates have a high degree of uncertainty.
Recent Initiatives: Focusing on advancing its clinical trials for REVTx-99a and REVTx-300, and pursuing potential partnerships or collaborations.
Summary
Revelation Biosciences is a clinical-stage biopharmaceutical company focused on developing immunologic-based therapies. Currently, the company has no revenue and is dependent on the success of their clinical trials. Clinical trial success would put them in position to compete with established pharmaceutical companies. Dependence on clinical trial success and access to funding are their biggest challenges. The company must manage competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Financial News Outlets
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Investment decisions should be based on thorough due diligence and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Revelation Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-11-17 | Chairman & CEO Mr. James M. Rolke | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.revbiosciences.com |
Full time employees 8 | Website https://www.revbiosciences.com | ||
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.